| Similar Articles |
|---|
 |
The Motley Fool
November 29, 2004
Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year.   |
The Motley Fool
March 3, 2005
Brian Gorman |
Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors. |
The Motley Fool
September 5, 2006
Brian Gorman |
Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list. |
The Motley Fool
April 2, 2004
Brian Gorman |
Bayer's Food Fight Bayer's recent U.K. troubles reflect Europe's continued distaste for genetically modified foods. |
The Motley Fool
February 12, 2010
Brian Orelli |
Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner. |
Chemistry World
May 9, 2014
Andy Extance |
Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener. |
The Motley Fool
August 30, 2004 |
Who's in the Dow? Did you realize that the Dow is an average of just 30 companies? |
The Motley Fool
March 31, 2004
W.D. Crotty |
Monsanto in the Balance Genetically modified crops are a boon for the company. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
April 19, 2004
W.D. Crotty |
3M: Money, Margins, Magnificent Trusty old 3M is no ordinary industrial conglomerate. |
The Motley Fool
January 28, 2004
W.D. Crotty |
Playing DuPont Ping-Pong What's an investor to make of DuPont's ping-pong strategy? |
The Motley Fool
May 19, 2004
Brian Gorman |
U.N. Plants Seed for Agribusiness Its endorsement of biotech foods could clear the way for agribusiness in the developing world. |
Chemistry World
September 23, 2014
Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months. |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business. |
The Motley Fool
August 29, 2006
S.J. Caplan |
Bayer's Crop Headache The company's second-quarter earnings are up while crops drag. Investors, take note. |
The Motley Fool
March 11, 2004
Bill Mann |
Pennsylvania Sues Drug Makers Anyone who thinks that the new prescription drug benefit plan (the Medicare Modernization Act) signed by President Bush will have anything resembling predictable expenses needs to pay attention to what's going on in Pennsylvania. The commonwealth filed suit yesterday against 13 large drug companies, accusing them of price manipulation. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
May 18, 2011
Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool
May 18, 2009
Brian Orelli |
Onyx Cries, "Et Tu, Brute?" The company is suing for the rights to a drug that marketing partner Bayer is developing. |
The Motley Fool
August 27, 2007
Brian Orelli |
Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up. |
Chemistry World
November 16, 2012
Andrew Turley |
What lies within Bayer is looking to 'modestly' increase its R&D budget next year -- it was 3 billion euros( 2.4 billion pounds) for 2012 -- and place new emphasis on transferring ideas between research areas within the company. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
October 13, 2011
Sean Williams |
How to Turn Onyx Into Gold A settlement with Bayer turns Onyx into an instant buyout candidate. |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
February 22, 2006
Rich Smith |
1001 Teutonic Nights, Part 2 Investors, get to know Germany: BASF... Bayer... SGL Carbon... Pfeiffer Vacuum... |
The Motley Fool
December 5, 2006
Brian Lawler |
Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
May 8, 2009
Brian Orelli |
Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out. |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
BusinessWeek
June 23, 2011
Naomi Kresge |
Bayer Aspirin Is Feeling Plenty Healthy While J&J's Tylenol recovers from a recall, sales of century-old Bayer are soaring. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
June 3, 2011
Brian Orelli |
Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up. |
The Motley Fool
September 23, 2009
Brian Orelli |
Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer. |
The Motley Fool
March 15, 2004
W.D. Crotty |
60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks? |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
Chemistry World
June 30, 2015
Phillip Broadwith |
What's in a name? How should one go about making up a word for a new company name? Two recent spin-offs from large chemical companies demonstrate different strategies. |
Chemistry World
October 5, 2012
Phhillip Broadwith |
Bayer and Evotec team up on endometriosis Bayer Healthcare and Evotec have agreed to collaborate in their search for drugs for endometriosis, a disease in which cells of the type that normally line the uterus wall grow outside of the womb. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
IndustryWeek
September 1, 2002
John S. McClenahen |
Bayer's Formula: Two Sites Both Research Triangle Park, N.C., and Kansas City, Mo., are home to newly created Bayer CropScience's North American Operations. |
The Motley Fool
February 24, 2009
Brian Orelli |
Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter. |
IndustryWeek
January 19, 2011 |
Bayer's Prescription: More Innovation, Less Administration Bayer stokes product pipeline and sees accelerated growth in emerging markets. |
The Motley Fool
February 26, 2004
Seth Jayson |
Men's Wearhouse's Boring Success The clothier posts impressive fourth-quarter and full-year results. |
The Motley Fool
October 3, 2008
Brian Orelli |
Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
November 8, 2007
Brian Orelli |
Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note. |
The Motley Fool
October 28, 2009
Brian Orelli |
Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
May 12, 2004
Seth Jayson |
Firming Up at Federated Decent sales, decent comps, decent earnings. Maybe there is a bargain in retail. |
